The 10 Mistakes US MedTech Companies Make When Entering Europe

European MedTech Market Opportunity

• European medical technology market value: ~ €170 billion
• Europe is the world's second-largest MedTech market
• Germany, France, the UK, Italy and Spain are Europe's largest medical technology markets

1. Are You Assuming FDA Approval Is Enough for Europe?

One of the most common misconceptions among US medical device companies is that FDA approval will streamline European market entry. While FDA clearance demonstrates that a device meets regulatory standards in the United States, European Medical Device Regulation (EU MDR) requires its own compliance process.

Manufacturers often need additional clinical evidence, expanded technical documentation, post-market surveillance plans, and independent conformity assessments before obtaining CE marking. Companies that fail to understand these differences frequently experience launch delays and unexpected regulatory costs.

Many MedTech firms discover that the European regulatory pathway is significantly longer and more complex than originally anticipated, particularly under MDR.

MDR Certification Reality

According to the MedTech Europe 2024 Regulatory Survey, medical device manufacturers report average conformity assessment timelines of approximately 20-22 months. The survey also found that more than 50% of the assessment time is spent in pre-review and certificate issuance phases, highlighting administrative bottlenecks throughout the certification process.

Chart: Average MDR Certification Timeline

Figure 1. Average MDR Certification Timeline

2. Are You Underestimating MDR Compliance Costs?

Many executive teams budget primarily for certification fees without accounting for the significant internal effort required to achieve compliance.

In reality, most MDR-related costs stem from regulatory preparation activities such as clinical evaluations, documentation updates, quality management processes and compliance resources.

For growth-stage MedTech companies, these internal requirements can place considerable pressure on personnel and budgets.

What Drives MDR Costs?

According to the MedTech Europe 2024 Regulatory Survey, manufacturers reported that 90% of first-year IVDR/MDR certification-related costs were associated with personnel resources required to manage quality management systems (QMS), technical documentation (TD), and compliance processes. Notified Body fees represented approximately 7% of costs, while annual regulatory maintenance activities accounted for 3%.

Obtaining CE marking is a critical milestone, but it does not guarantee commercial success.

European healthcare systems place significant emphasis on reimbursement, economic value, and health technology assessments. Without a reimbursement pathway, many hospitals may be unable or unwilling to adopt a new device.

Healthcare organisations increasingly evaluate products based on:

• Clinical evidence
• Budget impact
• Patient outcomes
• Operational efficiency
• Long-term value creation
  
  

The most successful market-entry strategies consider reimbursement planning long before launch.

6. Are You Relying Too Heavily on Distributors?

Distributors can provide valuable market access, local knowledge and healthcare contacts. However, relying exclusively on distributors can create commercial blind spots.

Many MedTech companies lose visibility into:

• Customer feedback
• Competitive intelligence
• End-user relationships
• Pipeline performance
• Emerging market opportunities
  
  

This becomes especially problematic when distributors manage multiple competing product portfolios.

A hybrid approach that combines distributor support with direct business development activities often delivers stronger long-term results and provides greater market visibility.

7. Have You Failed to Adapt Your Value Proposition for European Buyers?

US healthcare buyers often focus heavily on innovation and performance.

European healthcare decision-makers frequently take a broader view.

Purchasing decisions may involve clinicians, procurement departments, administrators and reimbursement stakeholders, all of whom evaluate value differently.

Questions commonly asked include:

• Does this reduce healthcare costs?
• Will it improve patient outcomes?
• Can it increase operational efficiency?
• Does reimbursement support adoption?
  
  

European Purchasing Reality

Successful medical device sales often require alignment with multiple stakeholder groups, including clinical, procurement, economic and reimbursement decision-makers.

Companies that position themselves purely on innovation may struggle to gain traction without a strong economic case.

8. Are You Waiting Too Long to Build Local Relationships?

Europe remains a relationship-driven business environment, particularly within healthcare.

Building trust with key stakeholders often takes time and should begin long before launch activities.

Important stakeholders may include:

• Key Opinion Leaders (KOLs)
• Clinical specialists
• Procurement managers
• Hospital administrators
• Distribution partners
• Healthcare buying groups
  
  

Competitive Market Landscape

Europe is home to approximately 34,000 medical technology companies, with around 95% classified as SMEs, creating a highly competitive market environment.

Companies that begin stakeholder engagement early are often better positioned for successful market adoption.

9. Are You Underestimating Cultural and Language Differences?

Europe consists of dozens of distinct business cultures.

What resonates with a healthcare buyer in Germany may not resonate with buyers in France, Italy or the Nordic countries.

Simply translating sales collateral is rarely enough.

Figure 2.Typical Commercial Preferences by country

Successful MedTech companies localise their market approach rather than applying a one-size-fits-all European strategy.

10. Are You Expanding Without a Dedicated European Sales Strategy?

One of the costliest mistakes is treating Europe as a side project rather than a dedicated growth initiative.

Many companies receive regulatory approval only to realise they lack:

• Market intelligence
• Qualified leads
• Local sales coverage
• Distributor strategy
• Account development plans
  
  

Without a structured commercial strategy, generating sustainable growth becomes difficult.

For many organisations, commercial execution becomes a bigger challenge than regulatory approval itself. 

Key Insights

For US MedTech companies entering Europe, the biggest risks are rarely linked to product quality or innovation. More often, expansion challenges stem from regulatory complexity, reimbursement requirements, market fragmentation, cultural differences, and insufficient local commercial infrastructure.

Companies that prioritise market selection, regulatory preparation, stakeholder engagement, localisation and a dedicated European sales strategy are significantly more likely to achieve long-term success in Europe's healthcare market.

How EuroDev Can Help

Successfully entering Europe requires the right balance of market knowledge, local presence, and commercial execution. EuroDev supports North American MedTech and life sciences companies through Sales Outsourcing services that help accelerate market entry, build qualified pipelines, identify strategic partners, and drive sustainable growth across Europe. EuroDev has supported more than 500 North American organisations with European expansion initiatives.

Learn more about industries we support within MedTech & Life Sciences sector. Ready to discuss your European growth strategy? Contact our expert today.

Sources